Noteworthy

Mar 01, 2017
Leela Barham looks at NICE's new position statement, which seeks to set out more clearly how it works with industry.
Feb 28, 2017
Pharmaceutical Executive
A panel of biopharma executives responsible for the Latin America business discuss investment, market access, and reimbursement issues in this key regional growth market for the life sciences industry.
Feb 21, 2017
Pharmaceutical Executive
Outlining one country’s unique price-setting model for novel drugs—and the resulting pre-launch strategies for manufacturers.
Feb 09, 2017
Pharmaceutical Executive
Keith Bailey offers a new approach to reviving industry collaborations.
Feb 03, 2017
Pharmaceutical Executive
There are question marks when trying to size up the trajectory of the global pharma industry in 2017. One certainty, however, will be change.
Feb 01, 2017
Pharm Exec speaks to ICON's Ramita Tandon about how the UK and European regulators' market access plans for 2017 will affect the industry.
Jan 31, 2017
As the healthcare landscape evolves, pharmaceutical companies are being driven to embrace new, unique partnerships to go beyond the pill, writes Weng Si Ho.
Jan 23, 2017
Pharmaceutical Executive
Belén Garijo, CEO of Merck KGaA, Darmstadt, Germany’s healthcare business, shares her approach in transforming a traditional pharma unit focused on small molecules for chronic disease to a high-tech specialty producer of immunotherapy drugs for rare cancers.
Jan 18, 2017
Pharmaceutical Executive
With soaring valuations of companies in the public and M&A markets now a distant memory, the challenge for industry will be choosing the right mix of M&A, licensing, and partnering, writes Peter Young.
Jan 18, 2017
Pharmaceutical Executive
Connected ecosystems will change the future of healthcare. William King outlines three key value drivers.
native1_300x100
lorem ipsum